![]() These data provide the first evidence that we can improve on the rates of recurrence-free survival achieved by PD-1 blockade in resected high-risk melanoma. "The results of this randomized Phase 2b trial are exciting for the field. We look forward to advancing this program into the next phase of development." "Over the last six years, our teams have worked closely together combining our respective expertise in mRNA and immuno-oncology with a focus on improving outcomes for patients with cancer. Li, president, Merck Research Laboratories. "These positive findings represent an important milestone in our collaboration with Moderna," said Dr. We look forward to publishing the full data set and sharing the results at an upcoming oncology medical conference, as well as with health authorities." "We will begin additional studies in melanoma and other forms of cancer with the goal of bringing truly individualized cancer treatments to patients. mRNA has been transformative for COVID-19, and now, for the first time ever, we have demonstrated the potential for mRNA to have an impact on outcomes in a randomized clinical trial in melanoma," said Stéphane Bancel, Moderna's Chief Executive Officer. "Today's results are highly encouraging for the field of cancer treatment. Adjuvant treatment with mRNA-4157/V940 in combination with KEYTRUDA reduced the risk of recurrence or death by 44% (HR=0.56 one-sided p-value=0.0266) compared with KEYTRUDA alone. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced that the Phase 2b KEYNOTE-942/mRNA-4157-P201 trial of mRNA-4157/V940, an investigational personalized mRNA cancer vaccine, in combination with KEYTRUDA ®, Merck's anti-PD-1 therapy, demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of recurrence-free survival (RFS) versus KEYTRUDA alone for the adjuvant treatment of patients with stage III/IV melanoma following complete resection. Results are the first demonstration of efficacy for an investigational mRNA cancer treatment in a randomized clinical trialĬompanies plan to discuss results with regulatory authorities and initiate a Phase 3 study in melanoma in 2023 and rapidly expand to additional tumor typesĬAMBRIDGE, MA and RAHWAY, NJ / ACCESSWIRE / Decem/ Moderna, Inc. MRNA-4157/V940, in combination with KEYTRUDA, demonstrated a statistically significant and clinically meaningful reduction in the risk of disease recurrence or death compared to KEYTRUDA monotherapy in stage III/IV melanoma patients with high risk of recurrence following complete resection
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |